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Abstract
Background: The benefits of genomics and biotechnology are concentrated primarily in the
industrialized world, while their potential to combat neglected diseases in the developing world has
been largely untapped. Without building developing world biotechnology capacity to address local
health needs, this disparity will only intensify. To assess the potential of genomics to address health
needs in the developing world, the McLaughlin-Rotman Centre for Global Health, along with local
partners, organized five courses on Genomics and Public Health Policy in the developing world. The
overall objective of the courses was to collectively explore how to best harness genomics to
improve health in each region. This article presents and analyzes the recommendations from all five
courses.
Discussion: In this paper we analyze recommendations from 232 developing world experts from
58 countries who sought to answer how best to harness biotechnology to improve health in their
regions. We divide their recommendations into four categories: science; finance; ethics, society and
culture; and politics.
Summary: The Courses' recommendations can be summarized across the four categories listed
above:
Science: - Collaborate through national, regional, and international networks
- Survey and build capacity based on proven models through education, training, and needs
assessments
Finance: - Develop regulatory and intellectual property frameworks for commercialization of
biotechnology
- Enhance funding and affordability of biotechnology
- Improve the academic-industry interface and the role of small and medium enterprise
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Ethics, Society, Culture: - Develop public engagement strategies to inform and educate the
public about developments in genomics and biotechnology
- Develop capacity to address ethical, social and cultural issues
- Improve accessibility and equity
Politics: - Strengthen understanding, leadership and support at the political level for biotechnology
- Develop policies outlining national biotechnology strategy
These recommendations provide guidance for all those interested in supporting science, 
technology, and innovation to improve health in the developing world. Applying these 
recommendations broadly across sectors and regions will empower developing countries 
themselves to harness the benefits of biotechnology and genomics for billions who have long been 
excluded.
Background
Genomics and biotechnology hold great potential to fight
diseases that disproportionately affect the world's poorest
people. However, the benefits of biotechnology, driven by
market incentives of the industrialized world, have
accrued primarily to rich countries, with billions in the
developing world largely excluded from these advances.
Developing nations are now taking steps to build long-
term plans to benefit from biotechnology innovation [1].
In Africa, the African Union Commission President devel-
oped a High-Level Panel on Modern Biotechnology to
"generate a critical mass of technological expertise in tar-
geted areas that offer high growth potential" from bio-
technology and "harness biotechnology in order to
develop Africa's rich biodiversity...improv [e] agricultural
productivity and [develop] pharmaceutical products [2]."
In January 2007, the African Ministerial Council on Sci-
ence and Technology received the Panel report and com-
mitted themselves to a "20 year African Biotechnology
Strategy" to promote that vision. The Federation of Asian
Biotech Associations offers another Southern-based exam-
ple of "collaboration between industry and academia"
that seeks to "boost investment in biotechnology, interna-
tional trade in biotechnology products, and outsourcing
of services [3]." The need for developing countries to
develop and benefit from biotechnology is clear – as a dis-
cussion paper from the World Bank's recent Global Forum
on Science, Technology, and Innovation (STI) states, there
is no longer a question of whether countries should build
science and technology capacity that promotes biotech-
nology innovation, "but what type of capacity to build,
given their economic constraints, and how best to imple-
ment these capacity building action plans [4]."
Driven by a mission to harness the advances of innovative
technology for global health equity, the McLaughlin-Rot-
man Centre for Global Health (MRC), formerly the Cana-
dian Program on Genomics and Global Health, sought to
ask how developing countries can best harness health bio-
technology to improve health in their regions. We
define'genomics' as the powerful new wave of health-
related life sciences (biotechnologies) energized by the
Human Genome Project and the knowledge and tools it is
spawning (including proteomics, transcriptomics, metab-
olomics, etc). Our operational definition encompasses
the ethical, legal, social and cultural dimensions of devel-
oping the science and technologies and taking them to
where they were needed: from the lab to the village, as it
were. In this paper we use the terms 'biotechnology' and
'genomics' interchangeably. We first explored ways to har-
ness biotechnology to improve the health in the develop-
ing world in 2001, followed by a study that identified the
top ten biotechnologies for improving health in develop-
ing countries in 2002 [5,6]. Between 2002 and 2004, the
MRCGH planned, developed, and executed five Executive
Courses on Genomics and Public Health Policy in five
regions in the developing world. In this endeavor we col-
laborated with local experts and institutions to bring
together 232 developing world experts and key stakehold-
ers from multiple sectors to determine the best way to har-
ness genomics and health biotechnology to improve the
health of people in the developing world. Previous recom-
mendations on how to bring the benefits of biotechnol-
ogy to the poor have not focused on generating broadly
applicable guidelines for improving health, but rather on
enhancing particular technologies, such as agricultural
biotech [7,8] and nanotechnology [9], or providing action
steps for particular nations [10] or stakeholders (e.g. civil
society or research institutes) involved in promoting bio-
technology [11]. Moreover, rather than employing wide-
spread consultation with developing world experts to gen-
erate recommendations, existing proposals have come
from small-scale workshops without a developing world
focus [12,13], forums emphasizing development as
opposed to health, or publications by lone developing
world voices [9]. To our knowledge, never before has such
a large, multi-sectoral, Southern-based group of experts
been consulted on these issues. This paper offers a cross-BMC Public Health 2007, 7:346 http://www.biomedcentral.com/1471-2458/7/346
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comparison of their recommendations. The similitude of
these independently generated recommendations sup-
ports their robustness as answers to the five courses' over-
arching question: how can the developing world best
harness genomics and biotechnology to improve health?
Discussion
Executive Courses on Genomics and Public Policy
The Executive Courses on Genomics and Public Health
Policy took place between 2002 and 2004 for experts in
five regions of the developing world: Nairobi, Kenya with
the African Centre for Technology Studies for the African
continent; Kerala, India with Indian Council of Medical
Research for the Indian subcontinent; Muscat, Oman with
the World Health Organization's Regional Office for the
Eastern Mediterranean region (EMRO); Caracas, Vene-
zuela with the United Nations University's Biotechnology
for Latin America and the Caribbean (BIOLAC) and the
Pan American Health Organization for Latin America and
the Caribbean; and Hong Kong SAR China with the Uni-
versity of Hong Kong for the Western Pacific and South-
east Asia region.
The 232 participants from 58 countries (see Figure 1) were
chosen based on contacts identified through our previous
work related to this area including recommendations
from field experts leading to a subsequent snowball effect.
Thorough in-depth literature review and internet-based
searches were also conducted to select and validate our
participant choices. The participants were carefully
selected to represent a wide range of interests relevant to
biotechnology, with special consideration given to appro-
priately balancing geographical, gender and discipline/
specialty distribution. The sectors represented included:
- government representatives, health ministry officials,
- regulatory officials, legal experts,
- scientists from academic institutions and industry,
including the director of a national institute of genomics
in the developing world, and a member of the research
team that in 1997 cloned Dolly the sheep, the first animal
ever cloned from an adult mammalian cell,
- industry executives, biotechnology company representa-
tives,
Regional breakdown of participants in the Executive Courses on Genomics and Public Health Policy Figure 1
Regional breakdown of participants in the Executive Courses on Genomics and Public Health Policy.BMC Public Health 2007, 7:346 http://www.biomedcentral.com/1471-2458/7/346
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- members of non-governmental organizations (NGOs),
and media.
The executive courses had three goals:
1. To familiarize the participants with the current status
and implications of health genomics and biotechnology,
and to provide information relevant to public policy-mak-
ing in these fields.
2. To provide frameworks for analyzing and debating the
policy issues and related ethical questions in health
genomics and biotechnology, and to help people to
understand, anticipate and influence the legal and regula-
tory frameworks under which health biotechnology
industries will operate, both nationally and internation-
ally.
3. To begin developing a leaders' network reaching across
different sectors (including industry, academic, govern-
ment and NGOs) by sharing perspectives and building
relationships.
The courses, each lasting four, intensive, interactive days,
consisted of a series of presentations, primarily delivered
by local experts, and discussions led by stakeholders from
different countries and sectors, allowing for the opportu-
nity to express different viewpoints They provided oppor-
tunities to share information about the research, ethics,
social context, infrastructure, media relations, business
development, and regulations affecting the development
of biotechnology, and gave the participants background
information. However, the main question, 'how best to
harness biotechnology to improve global health,' and the
regional recommendations were developed in small and
large group discussions of the participants. Topics
included scientific advances in biotechnology, innova-
tions in business models, public sector perspectives, eth-
ics, legal issues, and national innovation systems. This
information is critical for developing countries if they are
to absorb and control research information and public
policy issues affecting major technological breakthroughs
in the life sciences and public health.
Participants drove the process of identifying and collect-
ing these recommendations. Participants constructed the
recommendations by:
1. pre-drafting recommendations based on presentations;
2. deleting any recommendations which the group did
not support;
3. adding missing recommendations;
4. sharpening recommendation language; and
5. attaining general or widespread agreement among par-
ticipants.
Participants received evaluation forms at the end of each
course. The general consensus reflected success in terms of
achieving the goals and objectives of the Courses, with sat-
isfaction ratings by the participants ranging from 86%-
96%. The first three courses have been published individ-
ually without a synthesis of the recommendations as a
whole [14-16]. This paper, however, compares and ana-
lyzes recommendations from all five courses.
Recommendations from the Course Participants
In each course, working groups were asked for advice on
developing genomics/biotechnology in the region to
improve public health as outlined above. One of the
products from each course was a set of recommendations
on how best to harness biotechnology to address local
health needs within their region. The recommendations
are intended for use by policy-makers, industry leaders,
scientists, health care providers, NGOs, and funding agen-
cies. We applied these categories retrospectively to the
Courses after developing them in consultation with devel-
oping world key informants in 2006. We compared and
analyzed the Courses' recommendations and synthesized
them into four categories as presented below: 1) science,
2) finance, 3) ethics, society, and culture, and 4) politics.
These categories, while not completely mutually exclu-
sive, help to present the recommendations of the 5
groups.
Science
Within the recommendations related to science, partici-
pants focused on the potential of inter-sectoral, regional,
and international collaboration to build capacity, the
need for surveys of current capacity, and the importance
of looking to successful models elsewhere. Participants
specifically called for collaboration and capacity-building
as methods to improve science education and establish
regional and international networks – these networks pos-
sess the much needed capacity to increase dialogue
between biotechnology developers and end-users. India's
lack of emphasis on regional collaboration is likely linked
to the fact that it was the only Course whose participants
all came from one nation. Africa and Latin America,
whose biotechnology capacities are comparatively less
developed, both encouraged their regions to look to suc-
cessful models of biotechnology innovation elsewhere
([17] see Table 1).
Finance
Key issues that arose regarding finance included regula-
tory systems, intellectual property rights, and private sec-B
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Table 1: Scientific Recommendations
Africa India Eastern Mediterranean Latin America and the Caribbean Western Pacific/Southeast Asia
-Establish a regional network to 
foster sustained inter-sectoral 
dialogue
- Commission African capacity 
survey in genomics-related R&D 
to determine areas of strength
- Undertake a detailed study of 
R&D models with demonstrated 
success in the developing world
- Establish seven regional research 
centres of excellence
- Improve industry-academic 
interface with appropriate 
incentives to improve public health 
and the nation's wealth
- Establish an internet-based opinion 
leaders' network to foster cross-
sectoral dialogue
- Provide coordination and 
networking among national 
biotechnology bodies and 
coordinators to exchange information, 
expertise, and training
- Regional cooperation in 
production and utilization of health 
biotechnology
- Coordinate a national survey/
inventory/situation analysis/needs 
assessment of health 
biotechnology innovation systems, 
including scientific and management 
capacity, government policies, 
legislation and regulations, intellectual 
property policies, private sector 
activity, and strengths/weaknesses, 
opportunities and threats
- Encourage academic institutions to 
include health biotechnology 
topics within their curricula and 
create specialized programs and 
degrees where appropriate. There 
should be particular emphasis on ICT 
and bioinformatics
- Conduct a study both to document 
system's strengths in genomics and 
biotechnology and also to determine the 
needs which can be addressed by these 
disciplines
- Educate and prepare the necessary 
human resources in genomics and 
biotechnology
- Seek help and advice from 
institutions in other countries in the 
region that have had a successful 
experience in this endeavor
-Develop mechanisms of regional 
cooperation to harness genomics and 
biotechnology for both health and 
economic development
- Harness the potential of Latin 
America and the Caribbean in genomics 
and biotechnology to improve health for 
the population of the region
- Build on existing networks so as to 
avoid duplications and redundancies
- Encourage the participation of 
researchers, government officials, 
members of the private sector, members 
of civil society, and any other relevant 
stakeholders
- Address local health needs
- Should not only pursue pure research but 
also applied problem solving 
investigation and product development
- Facilitate learning
- A strategy and a plan of action should 
be built at the regional level in order to 
promote the creation of international, 
interdisciplinary, multidisciplinary, and 
multi-institutional projects
- Seek development funds from 
national, regional and 
international sources
- Perform foresight exercises, 
including prioritization, needs 
assessment and action plan
- Facilitate linkages between 
government, academia, NGO's, civil 
society, researchers, the health system 
and industry
- Build capacity and share core 
facilities
- Develop joint training programs
- Identify existing genomics/
biotechnology capacity including 
trained personnel, equipment, etc. in 
all public and private sectors
- Build essential core research 
facilities linked to local needs
- Develop training programs for 
different personnel categories
- Integrate genomics/
biotechnology in curricula 
beginning at a primary level to 
postgraduate levelsBMC Public Health 2007, 7:346 http://www.biomedcentral.com/1471-2458/7/346
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tor collaboration. Participants stressed the need to harness
the power of biotechnology not only for health, but also
for economic development. Several regions stressed the
need to identify appropriate entry points for biotechnol-
ogy products and exploit domestic and regional markets
[6]. India's lack of emphasis on product entry may be due
to the fact that its private sector's affordable pharmaceuti-
cals have already emerged competitively in domestic and
global markets ([18] see Table 2).
Ethics, Society and Culture
Courses commenting on ESC issues called for public
engagement programs that would inform and educate
their populations on biotechnology developments.
Another common theme included the need for capacity to
address ethical issues including legal, social, and environ-
mental concerns. Participants also underscored themes of
accessibility and equity in terms of disseminating biotech-
nology innovations (see Table 3).
Politics
Political recommendations from participants highlighted
political leadership as a core factor in promoting biotech-
nology research and development in their regions. Many
participants stressed the need for national strategy and
public policy on genomics and biotechnology. African
participants recommended using the established New
Partnership for Africa's Development (NEPAD) as an
entry point onto the continent's political agenda. Several
regions also stressed the need for government support in
funding and developing biotechnology (see Table 4).
Summary
Although the recommendations from the five courses dis-
play nuances linked to regional differences in biotechnol-
ogy capacity and development, financial conditions,
political frameworks, and population needs, fundamental
lessons emerge from their insights. These lessons reinforce
the results of another study rooted in developing world
expert insights that highlighted the same four key forces:
science; finance; ethics, society, and culture; and politics.
The similitude of the Courses' recommendations, despite
their independent generation in five different regions by
over 200 participants, affirms the robustness of our
answer to how genomics and biotechnology can best
serve the health of the world's poorest people. Below is a
summary of their recommendations based on those
groupings (see Table 5).
Already, the courses have spurred development of bio-
technology capacity in the developing world. Beyond the
generation of recommendations, the Courses produced a
network for future collaboration. For example, an Indian
participant invited to speak at the EMRO Course
explained that although the Course occurred amidst
Indian-Pakistani tensions, his presentation received a
"warm response" from Pakistani delegates that led not
only to the bulk transfer of the hepatitis B vaccines from
India to Pakistan, but also the technology transfer that
facilitated their manufacture in Pakistan [19]. "Every
small cooperation matters," he said. "Science does not
have borders." Beyond this example of collaboration, the
EMRO Ministers of Health adopted the recommendations
from that meeting and in the Latin America and Carib-
bean region, the Pan American Health Organization
(PAHO) followed up with discussions of the recommen-
dations from that event. The Courses have also stimulated
international academic exchange – both bringing partici-
pants to Canadian institutions as well as funding graduate
study abroad. Following the courses, both participants
and the MRCGH staff have played advisory roles for one
another in subsequent research projects.
We recognize that the structure of the Courses limits the
rigor of the processes which generated these recommen-
dations – although participants reached consensus
through discussion, there was no formal consensus proc-
ess. The Courses are rooted in opinions rather than eco-
nomic or scientific analysis. Theoretically, had the
Courses involved a different set of participants, the results
might have differed. However, compared to the alterna-
tive of conducting surveys with 232 respondents from 58
countries, we feel the courses generated a more sustained
engagement with participants.
This study serves to offer a taxonomy of potential actions
for harnessing biotechnology to improve health; however,
some countries are already attempting to deal with the
challenges listed above. Ongoing studies at our Centre
indicate that the Brazilian government has been trying to
stimulate interactions between the public and private sec-
tor, specifically through the creation of an innovation law
meant to facilitate interactions between academia and
industry – due to this intervention, more and more private
companies are tapping into services within universities for
research and product development. With regard to the
challenge of intellectual property management, a recent
report from Médecins sans Frontières calls for developing
countries to look to the success of Brazil and Thailand in
issuing compulsory licenses [20].
These recommendations will be useful to all those inter-
ested in supporting science, technology, and innovation
to improve health in the developing world – both for
industrialized nations interested in supporting knowl-
edge-based approaches to science and developing nations
looking to foster biotechnology innovation. Across the
sectors of academia, government, industry, and civil soci-
ety, scientists, policymakers, regulators, venture capitalB
M
C
 
P
u
b
l
i
c
 
H
e
a
l
t
h
 
2
0
0
7
,
 
7
:
3
4
6
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
4
5
8
/
7
/
3
4
6
P
a
g
e
 
7
 
o
f
 
9
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 2: Financial Recommendations
Africa India Eastern Mediterranean Latin America and the Caribbean Western Pacific/Southeast Asia
- Create sustainable financing 
mechanisms
- Develop independent, 
accountable, transparent 
regulatory systems [...] for a single 
entry, smart and effective system
- Improve industry-academic 
interface with appropriate incentives 
to improve public health and the 
nation's wealth
- Increase [government] funding for 
healthcare research with appropriate 
emphasis on genomics
- Coordinate a national survey/
inventory/situation analysis/needs 
assessment of health biotechnology 
innovation systems, regulations, 
intellectual property policies, 
private sector activity, and 
strengths/weaknesses, opportunities 
and threats
- Develop a proposal for a Regional 
Genomics and Health Research 
Fund emphasizing both peer-reviewed 
research and capacity strengthening
- The National Commission on 
Biotechnology, in collaboration with 
the relevant ministries, should 
develop a plan to integrate 
genetic and genomics products 
(including diagnostics, vaccines, 
therapies, and other genomic 
priorities), within the health system and 
public health programs
- Develop mechanisms of regional 
cooperation to harness genomics and 
biotechnology for both health and 
economic development. The 
networks should not only pursue pure 
research but also applied problem solving 
investigation and product 
development
- Facilitate the development of guidelines 
on intellectual property, biosafety, 
bioethics, regulation, and public 
awareness
- Adopt a strategic point of entry into 
genomics and biotechnology. 
Bioinformatics is one such potential point 
of entry; others should be identified 
through foresight exercises conducted in 
the region
- Domestic small and medium 
enterprises in the region should form 
strategic alliances and joint ventures, 
with special emphasis on bringing 
together organizations from different 
countries in the region
- Identification of cheaper alternative 
sources of energy
- Develop and harmonize regulatory 
policies including IP, biodiversity 
management, biosafety, movement of 
genetic material, protection of 
indigenous knowledge
- Create innovative business models 
for economic and health care 
development and to support research
- Identify appropriate entry points for 
genomics/biotechnology (e.g. various 
forms of agriculture, genetic screening, 
traditional medicine, bioinformatics, 
diagnostics for infectious diseases, etc)
- Explore formation of public-private 
partnerships to address regional and 
national health needs
Table 3: ESC Recommendations
Africa India Eastern Mediterranean Latin America and the Caribbean Western Pacific/Southeast Asia
N/A - Engage the public and ensure 
broad-based input into policy setting
- Ensure equitable access of poor to 
genomics products and services
- Develop independent, accountable, 
transparent regulatory systems... based 
on ethics to ensure that ethical, 
legal and social issues are 
addressed
- The National Commission on 
Biotechnology should develop 
programs of public awareness and 
engagement. Important "publics" 
here include media and religious 
leaders as well as the public at large. 
The discussion should include ethical 
issues
- The emphasis should be on 
accessibility and equity to improve 
the health of the poor
- The population of the countries in 
the region should be informed and 
educated about the developments in 
genomics and biotechnology, and in the 
impact of these disciplines in addressing 
local health needs
- Engage their publics in ways that 
inform, seek feedback and use the 
feedback to inform policy
- Increase capacity for research and 
development on ethical, legal, 
environmental and social 
implicationsB
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Table 4: Political Recommendations
Africa India Eastern Mediterranean Latin America and the Caribbean Western Pacific/Southeast Asia
- Identify champions among 
politicians
- Use the New Plan for African 
Development (NEPAD) as entry 
point onto political agenda
- Increase [government] funding for 
healthcare research with appropriate 
emphasis on genomics
- Create National Commission on 
Genomics, Biotechnology and Health, 
multisectoral membership include 
youth, women, and civil society. The 
focus should include ethical issues
- Based on evidence from the national 
survey described above, governments 
of member states should develop and 
adopt, at the highest level, a national 
biotechnology strategy
- Regional Director EMRO may be 
requested to address the 
governments at the highest level 
for actively considering the proposals 
of this workshop and for giving priority 
attention to genomics for health and 
health biotechnology. The political 
leadership may be provided 
effective advocacy material, with 
special reference to its link with 
poverty alleviation, public health 
objectives, and need for transfer (and 
internalization) of technology
- Create, at the local and regional 
levels, a strategy to strengthen 
capacity in science, in technology, and 
in management
-Establish a concrete genomics 
and biotechnology public policy, a 
strategy, and a plan of action to 
develop and use these disciplines to 
address the country's most pressing 
health problems
- Build strategy at the regional 
level in order to promote the creation 
of international, interdisciplinary, 
multidisciplinary, and multi-institutional 
projects
-Coordinate/undertake/conduct 
strategic planning aimed at achieving 
sustainability of programs using 
measurable benchmarks for desired 
regional and national outcomes
- Encourage proactive government 
support
- Advocate for public and private 
support
Table 5: Summary Table of Recommendations from the Executive Courses on Genomics and Public Health Policy
Recommendations to Harness Genomics for Health in Developing Countries
SCIENCE
• Collaborate through national, regional, and international networks
• Survey and build capacity based on proven models through education, training, and needs assessments
FINANCE
• Develop regulatory and intellectual property frameworks for commercialization of biotechnology
• Enhance funding and affordability of biotechnology
• Improve the academic-industry interface and the role of small and medium enterprise
ETHICS, SOCIETY, CULTURE
• Develop public engagement strategies to inform and educate the public about developments in genomics and biotechnology
• Develop capacity to address ethical, social and cultural issues
• Improve accessibility and equity
POLITICS
• Strengthen understanding, leadership and support at the political level for biotechnology
• Develop policies outlining national biotechnology strategyPublish with BioMed Central    and   every 
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firms, industry representatives, and donor communities
will benefit from the applications of these insights.
Biotechnology can act both as a catalyst to foster overall
development of science and technology as well as the
development of practical solutions to local health needs.
These recommendations align holistically and act as
forces that will affect the development and adoption of
health biotechnology in the developing world [21].
Applying these recommendations broadly across sectors
and regions will empower developing countries them-
selves to harness the benefits of biotechnology and
genomics for billions who have long been excluded.
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